Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plan B Restrictions Set “Unique Example” Experts Say, But What May Follow?

This article was originally published in The Tan Sheet

Executive Summary

Barr's postmarketing commitment for Plan B's newly approved behind-the-counter (BTC) sale status may be the most innovative and closely-watched element of the switch and the drug's planned dual-marketing campaign
Advertisement

Related Content

Bush’s “Conscience” Rule Limiting Plan B Access On HHS Chopping Block
Daschle’s Prescription For FDA: Leadership, Policy, Funding And Coordination
Behind-The-Counter Guidance Stalled, But Interest Grows To Expand Access
Von Eschenbach Promotes Behind-The-Counter Drug Class
U.K. Proposes Prescription-Only Status For Pseudoephedrine Products
Alli Approved OTC For Weight Loss With “Goal Oriented” Indication
NDAC Panelists Look At Future Of Behavior Research For OTC Postmarket
Barr Takes CARE To Monitor Plan B Consumer Behavior Trends
Plan B Pioneers OTC “Pharmacy Counter” Approval, Dual-Status Marketing
Plan B Pioneers OTC “Pharmacy Counter” Approval, Dual-Status Marketing

Topics

Advertisement
UsernamePublicRestriction

Register

PS099743

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel